We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Perspective

Remote endarterectomy for occlusive iliac and superficial femoral artery disease

    Luuk Smeets

    † Author for correspondence

    Twenteborg Hospital, Department of Surgery, Zilvermeeuw 1, 7609 PP Almelo, The Netherlands.

    Search for more papers by this author

    Email the corresponding author at l.smeets@zgt.nl

    ,
    Gwan H Ho

    Amphia Hospital, Department of Vascular Surgery, Breda, The Netherlands.

    Search for more papers by this author

    &
    Frans L Moll

    University Medical Centre, Department of Vascular Surgery, PO Box 85500, 3508 GA, Utrecht, The Netherlands.

    Search for more papers by this author

    Email the corresponding author at f.l.moll@chir.azu.nl

    Published Online:20 Dec 2006https://doi.org/10.2217/14796678.3.1.43

    Abstract

    Today’s patients increasingly desire a low-risk procedure with rapid return to functional status following surgery. Many patients actively seek a minimally invasive option. During the last decade, minimally invasive surgical and radiological procedures emerged from their infancy to become an integral part of the treatment strategy in both peripheral arterial occlusive disease and aneurysmal arterial disease. The trend towards restoration of luminal patency, using the vessel itself as a conduit, can also be termed restorative intervention. As radiological percutaneous transluminal angioplasty has thus far proven unsuccessful in the long term for iliac and femoropopliteal occlusive lesions exceeding 10 cm, a new endovascular surgical procedure has been developed. A modification to the original ringstripper, used in semiclosed endarterectomy, was made to enable the technique of remote endarterectomy.

    Bibliography

    • 1  TASC Working group: D4 treatment of critical limb ischaemia. Trans-Atlantic Inter-Society Consensus (TASC). J. Vasc. Surg.31,S1–S289 (2000).
      MedlineGoogle Scholar
    • 2  Ho GH: Endovascular remote endarterectomy: initial experience with a new technique in the treatment of superficial femoral artery occlusive disease. Thesis, Utrecht, The Netherlands, ISBN 90-393-2010-1 (1999).
      Google Scholar
    • 3  Green RM, Abbot WM, Matsumoto T et al.: Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J. Vasc. Surg.31,417–425 (2000).
      Medline CASGoogle Scholar
    • 4  Johnson WC, Lee KK: A comparative evaluation of polytetrafluorethylene, umbilical vein and saphenous vein bypass grafts for femoral-popliteal above knee revascularization. A prospective randomized department of veterans affairs cooperative study. J. Vasc. Surg.32,268–277 (2000).
      Medline CASGoogle Scholar
    • 5  Klinkert P, Schepers A, Burger DC, van Bockel JH, Breslau PJ: Vein versus polytetrafluorethylene in above-knee femoropopliteal bypass grafting: five year results of a randomized controlled trial. J. Vasc. Surg.37,149–155 (2003).
      MedlineGoogle Scholar
    • 6  Klinkert P, Oost PN, Breslau PJ, van Bockel JH: Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of literature. Eur. J.  Vasc. Endovasc. Surg.27,357–362 (2004).
      Medline CASGoogle Scholar
    • 7  Devine C, McCollum C, on behalf of The North West Femoro-Popliteal Trial Participants: Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J. Vasc. Surg.40,924–931 (2004).
      MedlineGoogle Scholar
    • 8  Hamsho A, Nott D, Harris PL: Prospective randomized trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass. Eur. J. Vasc. Endovasc. Surg.17,197–201 (1999).
      Medline CASGoogle Scholar
    • 9  Rutherford RB, Baker JD, Ernst C et al.: Recommended standards for reports dealing with lower extremity ischemia: revised version. J. Vasc. Surg.26,517–518 (1997).
      Medline CASGoogle Scholar
    • 10  Ho GH, van Buren PA, Moll FL, van der Bom JG, Eikelboom BC: The importance of revision of early restenosis after endovascular remote endarterectomy in SFA occlusive disease. Eur. J. Vasc. Endovasc. Surg.19(1),35–42 (2000).
      Medline CASGoogle Scholar
    • 11  Martin JD: Presented at: 29th Annual Meeting of the Southern Association for Vascular Surgery. Marco Island, FL, USA, 19–22 January (2005).
      Google Scholar
    • 12  Rosenthal D, Schubart PJ, Kinney EV et al.: Remote superficial femoral artery endarterectomy: multicentre medium-term results. J. Vasc. Surg.43,428–432 (2001).
      Google Scholar
    • 13  Galland RB, Whiteley MS, Gibson M, Simmons MJ, Torrie EP, Magee TR: Remote superficial femoral artery endarterectomy: medium-term results. Eur. J. Vasc. Surg.19,278–282 (2000).
      CASGoogle Scholar
    • 14  Nelson PR, Powell RJ, Proia RR et al.: Results of endovascular superficial femoral endarterectomy. Vasc. Surg.34(3),526–531 (2001).
      CASGoogle Scholar
    • 15  Ho GH, Moll FL, Joosten PP, van de Pavoordt ED, Overtoom TT: The MollRing Cutter remote endarterectomy: preliminary experience with a new endovascular technique for treatment of occlusive superficial femoral artery disease. J. Endovasc. Surg.2(3),278–287 (1995).
      Medline CASGoogle Scholar
    • 16  Smeets L, de Borst GJ, de Vries JPPM, van den Berg JC, Ho GH, Moll FL: Remote iliac artery endarterectomy: seven year results of a less invasive technique for occlusive iliac artery disease. J. Vasc. Surg.38,1297–1304 (2003).
      MedlineGoogle Scholar
    • 17  van den Dungen JJ, Boontje AH, Kropveld A: Unilateral iliofemoral occlusive disease: Long-term results of the semiclosed endarterectomy with the ringstripper. J. Vasc. Surg.14,673–677 (1991).
      Medline CASGoogle Scholar
    • 18  Bell DD, Gaspar MR, Movius HJ, Rosental JJ, Lemic GG: Retroperitoneal exposure of the terminal aorta and iliac arteries. Am. J. Surg.138,254–256 (1979).
      Medline CASGoogle Scholar
    • 19  Smeets L, Ho GH, Hagenaars T, van den Berg JC, Teijink JA, Moll FL: Remote endarterectomy: first choice in surgical treatment of long segmental SFA occlusive disease? Eur. J. Vasc. Endovasc. Surg.25,583–589 (2003).
      Medline CASGoogle Scholar
    • 20  Piotrowski JJ, Pearce WH, Jones DN et al.: Aortobifemoral bypass: the operation of choice for unilateral iliac occlusion? J. Vasc. Surg.8,211–218 (1988).
      Medline CASGoogle Scholar
    • 21  Oliviera M, Wilson E, Williams R, Freischlag JA: Iliofemoral bypass: a 10-year review. Cardiovasc. Surg.1(2),103–106 (1993).
      MedlineGoogle Scholar
    • 22  Naylor AR, Ah-See AK, Engeset J: Graft occlusion following aortofemoral bypass for peripheral ischemia. Br. J. Surg.76,572–575 (1989).
      Medline CASGoogle Scholar
    • 23  Schouten O, Hoedt MT, Wittens CH, Hop WC, van Sambeek MR, van Urk H, on behalf of the VASCAN study group: End-to-end versus end-to-side distal anastomosis in femoropopliteal bypasses; results of a randomized multicenter trial. Eur. J. Vasc. Endovasc. Surg.29,457–462 (2005).
      Medline CASGoogle Scholar
    • 24  Berglund J, Björck M, Elfström J, on behalf of the SWEDVASC Femoro-popliteal Study Group: Long-term results of above knee femoro-popliteal bypass depend on indication for surgery and graft-material. Eur. J. Vasc. Endovasc. Surg.29,412–418 (2005).
      Medline CASGoogle Scholar
    • 25  Smeets L, Ho GH, Tangelder MJD et al., on behalf of the Dutch BOA study group: Outcome after occlusion of infrainguinal bypasses in the Dutch BOA study: comparison of amputation rate in venous and prosthetic grafts. Eur. J. Vasc. Endovasc. Surg.30(6),604–609 (2005).
      Medline CASGoogle Scholar
    • 26  Ballotta E, Renon L, Toffano M, Da Giau G: Prospective randomized study on bilateral above-knee femoropopliteal revascularization: polytetrafluoroethylene graft verses reversed saphenous vein. J. Vasc. Surg.38,1051–1055 (2003).
      MedlineGoogle Scholar
    • 27  Jackson MR, Belott TP, Dickason T et al.: The consequences of a failed femoropopliteal bypass grafting: comparison of saphenous vein and PTFE grafts. J. Vasc. Surg.32(3),498–505 (2000).
      Medline CASGoogle Scholar
    • 28  AbuRahma AF, Robinson PA, Holt SM: Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. Surgery126,594–601 (1999).
      Medline CASGoogle Scholar
    • 29  van der Heijden FH, Eikelboom BC, van Reedt Dortland RW, van der Graaf P: Superficial femoral artery and the outcome of failed reconstructions. J. Vasc. Surg.8,271–279 (1993).
      Google Scholar
    • 30  John TG, Stonebridge PA, Kelman J, Murie JA, Jenkins AM, Ruckley CV: Above-knee femoropopliteal bypass grafts and the consequence of graft failure. Ann. Royal Coll. Surg. Engl.75,257–260 (1993).
      Medline CASGoogle Scholar
    • 31  O’Riordain DS, Buckley DJ, O’Donnel JA: Polytetrafluoroethylene in above-knee arterial bypass surgery for critical ischemia. Am. J. Surg.164,129–131 (1992).
      MedlineGoogle Scholar
    • 32  Blankensteijn JD, Van Vroonhoven TJ: Consequences of failure of femoropopliteal grafts for claudication. Eur. J. Vasc. Surg.2,183–189 (1988).
      Medline CASGoogle Scholar
    • 33  Brewster DC, LaSalle AJ, Robinson JG, Strayhorn EC, Darling RC: Femoropopliteal graft failures. Arch. Surg.118,1043–1047 (1983).
      Medline CASGoogle Scholar
    • 34  Klein WM, van der Graaf Y, Seegers J, Moll FL, Mali WP: Long-term cardiovascular morbididty and mortality after endovascular treatment in patients with iliac artery disease: the Dutch Iliac Stent Trial Study. Radiology232(2),491–498 (2004).
      MedlineGoogle Scholar
    • 35  Ng RL, Davies AH, Magee TR, Tennant S, Horrocks M, Baird RN: Early reoperation rates after arterial surgery. Eur. J. Vasc. Surg.8(1),78–82 (1994).
      Medline CASGoogle Scholar
    • 36  Kagan SA, Myers SI: Mediators of restenosis. Surg. Clin. North Am.78,481–500 (1998).
      Medline CASGoogle Scholar
    • 37  Leite PF, Liberman M, Sandoli de Brito F, Laurindo FR: Redox processes underlying the vascular repair reaction. World J. Surg.28,331–336 (2004).
      MedlineGoogle Scholar
    • 38  Azevedo LC, Pedro MA, Souza LC et al.: Oxidative stress as a signalling mechanism of the vascular response to injury: the redox hypotheis of restenosis. Cardiovasc. Res.47,436–445 (2000).
      Medline CASGoogle Scholar
    • 39  Freyschuss A, Stiko-Rahm A, Swedenborg J et al.: Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J. Clin. Invest.91,1282–1288 (1993).
      Medline CASGoogle Scholar
    • 40  Bandoh T, Mitani H, Niihashi M et al.: Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J. Cardiovasc. Pharmacol.35(1),136–144 (2000).
      Medline CASGoogle Scholar
    • 41  Jacob T, Ascher E, Alapat D, Olevskaia Y, Hingorani A: Activation of p38MAPK signaling cascade in a VSMC injury model: role of p38MAPK inhibitors in limiting VSMC proliferation. Eur. J. Vasc. Endovasc. Surg.29,470–478 (2005).
      Medline CASGoogle Scholar
    • 42  Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ: Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg.36,150–157 (1996).
      Google Scholar
    • 43  Deng YM, Wu BJ, Witting PK, Stocker R: Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation110(13),1855–1860 (2004).
      Medline CASGoogle Scholar
    • 44  Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J: Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg.29,171–176 (2005).
      Medline CASGoogle Scholar
    • 45  Goldman C, Salenius JP, Schmieder FA, Pilsudski R: Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a Phase I trial. J. Vasc. Surg.35(5),930–936 (2002).
      MedlineGoogle Scholar
    • 46  Lederman RJ, Mendelsohn FO, Anderson RD et al.: TRAFFIC investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet359(9323),2053–2058 (2002).
      Medline CASGoogle Scholar
    • 47  Arts CHP, de Groot PG, Slaper-Cortenbach ICM et al.: Research protocol “endothelial cell lining on prosthetic shunts evaluation (ECLIPSE-study)”. Thesis CHP Arts, Utrecht, The Netherlands, ISBN 90-393-3187-1 (2002).
      Google Scholar
    • 48  Knight JS, Smeets L, Morris GE, Moll FL: Multi centre study to assess the feasibility of a new covered stent and delivery system in combination with remote superficial femoral artery endarterectomy (RSFAE). Eur. J. Vasc. Endovasc. Surg.29,287–294 (2005).
      Medline CASGoogle Scholar
    • 49  Rosenthal D, Martin JD, Smeets L et al.: Remote superficial femoral artery endarterectomy and distal aSpire stenting: results of a multinational study at three year follow-up. J. Cardiovasc. Surg. (Torino)47(4),385–391 (2006).
      Medline CASGoogle Scholar
    • 50  Cheneau E, Rha SW, Kuchulakanti PK et al.: Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheter Cardiovasc. Interv.65(4),469–472 (2005).
      MedlineGoogle Scholar
    • 51  Grube E, Silber S, Haubtmana KE et al.: Two-year plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am. J. Cardiol.96(1),79–82 (2005).
      Medline CASGoogle Scholar
    • 52  Duda SH, Bosiers M, Lammer J et al.: Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J. Vasc. Interv. Radiol.16(3),331–338 (2005).
      MedlineGoogle Scholar
    • 53  Blanchemain N, Haulon S, Martel B, Traisnel M, Morcellet M, Hildebrand HF: Vascular PET prostheses surface modification with cycodextrin coating: development of a new drug delivery system. Eur. J. Vas. Endovasc. Surg.29,628–632 (2005).
      Medline CASGoogle Scholar
    • 54  Hou D, Narciso H, Kamdar K, Zhang P, Barclay B, March KL: Stent-based nitric-oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model. Cardiovasc. Intervent. Radiol.28(1),60–65 (2005).
      MedlineGoogle Scholar